BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sung JY, Kim GY, Lim SJ, Park YK, Kim YW. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract. 2010;206:24-29. [PMID: 19819644 DOI: 10.1016/j.prp.2009.07.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Ogorevc M, Strikic A, Tomas SZ. Determining the immunohistochemical expression of GLUT1 in renal cell carcinoma using the HSCORE method. Biomed Rep 2021;15:79. [PMID: 34429965 DOI: 10.3892/br.2021.1455] [Reference Citation Analysis]
2 Hong R, Lim SC. 18F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma. World J Gastroenterol 2012; 18(2): 168-174 [PMID: 22253523 DOI: 10.3748/wjg.v18.i2.168] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
3 Yu M, Yongzhi H, Chen S, Luo X, Lin Y, Zhou Y, Jin H, Hou B, Deng Y, Tu L, Jian Z. The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget 2017;8:43356-67. [PMID: 28498810 DOI: 10.18632/oncotarget.17445] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 18.7] [Reference Citation Analysis]
4 Rakheja D, Khokhar S, Mitui M, Cost NG. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors. Pediatr Dev Pathol 2012;15:286-92. [PMID: 22483234 DOI: 10.2350/12-01-1151-OA.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Cameron ME, Yakovenko A, Trevino JG. Glucose and Lactate Transport in Pancreatic Cancer: Glycolytic Metabolism Revisited. J Oncol 2018;2018:6214838. [PMID: 30631356 DOI: 10.1155/2018/6214838] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hommell-Fontaine J, Isaac S, Passot G, Decullier E, Traverse-Glehen A, Cotte E, You B, Mohamed F, Gilly FN, Glehen O, Berger F. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol 2013;20:3892-8. [PMID: 23800898 DOI: 10.1245/s10434-013-3077-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
7 Sharen G, Peng Y, Cheng H, Liu Y, Shi Y, Zhao J. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget 2017;8:19760-7. [PMID: 28178665 DOI: 10.18632/oncotarget.15035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
8 Liu R, Fu Z, Zhao M, Gao X, Li H, Mi Q, Liu P, Yang J, Yao Z, Gao Q. GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates. Oncotarget 2017;8:39476-96. [PMID: 28467806 DOI: 10.18632/oncotarget.17073] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
9 Takadate T, Onogawa T, Fukuda T, Motoi F, Suzuki T, Fujii K, Kihara M, Mikami S, Bando Y, Maeda S. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer. 2013;132:1368-1382. [PMID: 22915188 DOI: 10.1002/ijc.27797] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
10 Hashmi S, Wang Y, Suman DS, Parhar RS, Collison K, Conca W, Al-mohanna F, Gaugler R. Human cancer: Is it linked to dysfunctional lipid metabolism? Biochimica et Biophysica Acta (BBA) - General Subjects 2015;1850:352-64. [DOI: 10.1016/j.bbagen.2014.11.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
11 Kubo Y, Aishima S, Tanaka Y, Shindo K, Mizuuchi Y, Abe K, Shirabe K, Maehara Y, Honda H, Oda Y. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. Human Pathology 2014;45:1610-7. [DOI: 10.1016/j.humpath.2014.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
12 Shi J, Liu H, Wang HL, Prichard JW, Lin F. Diagnostic utility of von Hippel-Lindau gene product, maspin, IMP3, and S100P in adenocarcinoma of the gallbladder. Hum Pathol. 2013;44:503-511. [PMID: 23079206 DOI: 10.1016/j.humpath.2012.06.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
13 Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A Jr, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, Ajani JA. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology 2015;89:305-10. [PMID: 26393501 DOI: 10.1159/000436972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
14 Du J, Gu J, Deng J, Kong L, Guo Y, Jin C, Bao Y, Fu D, Li J. The Expression and Survival Significance of Glucose Transporter-1 in Pancreatic Cancer: Meta-Analysis, Bioinformatics Analysis and Retrospective Study. Cancer Invest 2021;:1-15. [PMID: 34229540 DOI: 10.1080/07357907.2021.1950755] [Reference Citation Analysis]
15 Yu M, Chen S, Hong W, Gu Y, Huang B, Lin Y, Zhou Y, Jin H, Deng Y, Tu L, Hou B, Jian Z. Prognostic role of glycolysis for cancer outcome: evidence from 86 studies. J Cancer Res Clin Oncol 2019;145:967-99. [DOI: 10.1007/s00432-019-02847-w] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 13.5] [Reference Citation Analysis]
16 Abouzeid AH, Patel NR, Rachman IM, Senn S, Torchilin VP. Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin. J Drug Target 2013;21:994-1000. [PMID: 24098980 DOI: 10.3109/1061186X.2013.840639] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
17 Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol. 2010;2010. [PMID: 20706540 DOI: 10.1155/2010/205357] [Cited by in Crossref: 93] [Cited by in F6Publishing: 95] [Article Influence: 8.5] [Reference Citation Analysis]
18 Wang J, Ye C, Chen C, Xiong H, Xie B, Zhou J, Chen Y, Zheng S, Wang L. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget 2017;8:16875-86. [PMID: 28187435 DOI: 10.18632/oncotarget.15171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 21.0] [Reference Citation Analysis]
19 Ansari D, Rosendahl A, Elebro J, Andersson R. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg. 2011;98:1041-1055. [PMID: 21644238 DOI: 10.1002/bjs.7574] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 7.4] [Reference Citation Analysis]
20 Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016;65:124-139. [PMID: 26773935 DOI: 10.1016/j.metabol.2015.10.007] [Cited by in Crossref: 179] [Cited by in F6Publishing: 175] [Article Influence: 29.8] [Reference Citation Analysis]
21 Jones RP, Bird NT, Smith RA, Palmer DH, Fenwick SW, Poston GJ, Malik HZ. Prognostic molecular markers in resected extrahepatic biliary tract cancers; a systematic review and meta-analysis of immunohistochemically detected biomarkers. Biomark Med 2015;9:763-75. [PMID: 26223884 DOI: 10.2217/BMM.15.48] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Moradi F, Iagaru A. The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer.Semin Nucl Med. 2020;50:434-446. [PMID: 32768007 DOI: 10.1053/j.semnuclmed.2020.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]